Patient Survey Results

The following data is compiled from five research studies conducted at Allergy Associates of La Crosse since 2003. The questionnaires were developed in coordination with the University of Wisconsin-La Crosse.

Demographic information for each year is listed below the findings.

The pediatric asthma study below was conducted with a graduate school researcher and presented at the 2005 American College of Allergy, Asthma and Immunology annual meeting. The review included 241 children ranging in age from one to six that were treated at Allergy Associates of La Crosse with sublingual immunotherapy drops following the La Crosse Method™ Protocol for at least two years.

KEY QUESTIONS	2003	2004	2005	2006^†	2013^*
Chronic Condition^ prior to coming to AAOL** Hypothesis: sublingual immunotherapy allows the treatment of patients that are significantly compromised by their allergies	51%	63%	73%	73%	N/A
Number of Dr visits now vs. prior to AAOL Hypothesis: actively treated sublingual immunotherapy patients will require less healthcare utilizations	48% less 1.19 v 3.69	68% less 1.61 v 5.01	60% less 2.2 v 5.5	58% less 1.9 v 4.5	82% less .65 v 3.56
ER visits now vs. prior to AAOL Hypothesis: actively treated sublingual immunotherapy patients will require less healthcare utilizations	80% less .15 v .76	81% less 11 v 57	86% less .1 v .7	58% less .6 v 1.4	95% less .02 v .41
Hospitalizations now vs. prior to AAOL Hypothesis: actively treated sublingual immunotherapy patients will require less healthcare utilizations	46% less .07 v .13	73% less 3 v 11	100% less 0 v .2	75% less .2 v .8	85% less .02 v .13
Medicine now vs. prior to AAOL Hypothesis: actively treated sublingual immunotherapy patients will require less healthcare utilizations	up to 50% less 2.19 v 2.59	50% less 1.62 v 3.23	40% less 1.5 v 2.5	13% less 2.7 v 3.1	47% less 5.46 v 10.21
School/work missed now vs. prior to AAOL Hypothesis: actively treated sublingual immunotherapy patients will require less healthcare utilizations	60% less 2.80 v 7.23	60% less 2.80 v 7.23	76% less .5 v 2.1	61% less 1.2 v 3.1	67% less 1 v 3
Quality of Life improved vs. prior to AAOL^*** Hypothesis: Does treatment via the La Crosse Method result in an improvement in the patients ability to participate in life (5 = very positively 4=quite positively 3 = some 2 = very little 1 = not at all)	4.11	4.47	4.5	4.2	4.11
Demographic Questions
Number of respondents Average age Tested for allergies before coming to AAOL Treated with other Immunotherapy before AAOL	250 46 48% 38%	75 47.5 54% 16%	112 38 60% 25%	212 71 47% 25%	299 36-55 N/A N/A

^† Medicare
^* The 2013 study was conducted in association with the University of Wisconsin-La Crosse. Some questions were not asked and are denoted by N/A.
^** Chronic Conditions that are caused by allergies: asthma, sinusitis, eczema, urticaria, etc.
^*** Respondents were asked to rate the impact of AAOL on their Quality of Life (QoL) on a scale of 1-5, 5 being the best. No respondents reported AAOL as negatively impacting their QoL.

2005 Pediatric Study Impact of Allergy Drops on children developing asthma

Hypothesis: La Crosse Method Protocol sublingual Immunotherapy has a significant impact on the development of asthma in children with allergic conditions

Allergic condition	Number of Children*
Allergic Rhinitis	201
Atopic Dermatitis	70
Wheeze	63
Inhalant Antigen	235
Animal Dander	120
Dust Mite	209
Egg White	209
Wheat	205
Alternaria (Mold)	48
Cases of Asthma post treatment at AAOL**	10

* Most children exhibited more than one condition
**This study was a retrospective chart review of 241 children who were diagnosed with at least one condition that is known to progress to asthma. About half of these 241 children could be expected to develop asthma. All patients received at least two years of treatment with the La Crosse Method Protocol at Allergy Associates of La Crosse. 10 children (4.1%) developed asthma.